HealthQuill US
The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.
Drugs Health Pharma

AstraZeneca, Amgen’s drug for nasal inflammation gets EU nod

The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.

Read More
China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development of its immuno-oncology and antibody-drug conjugate cancer therapies.
Drugs Health Pharma

China’s Innovent, Japan’s Takeda in $11.4 billion deal for cancer therapies

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.

Read More
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.
Drugs Health Pharma

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

Read More
US regulator rejects Fortress Biotech’s experimental pediatric medicine 
Drugs Medical Pharma

US regulator rejects Fortress Biotech’s experimental pediatric medicine 

The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production.

Read More
Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines in the North American nation
Drugs Medical Pharma

Pfizer inks deal with Trump to lower price of prescription drugs in US

Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines.

Read More
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight management and metabolism, and invest $50 billion in the country over five years.
Drugs Health Pharma

AstraZeneca to invest $50 billion in US, to build new drug facility

HQ Team July 22, 2025: Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight.

Read More